Pharmacology/Pharmaceutical Industry
Review: Pharmacologic management of persistent pain in cancer survivors.
6 May, 2022 | 10:34h | UTCPharmacologic Management of Persistent Pain in Cancer Survivors – Drugs
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
5 May, 2022 | 11:06h | UTCNews Release: Experts recommend additional cholesterol lowering drugs for adults at high heart disease risk – British Medical Journal
Medication errors, critical incidents, adverse drug events, and more: a review examining patient safety-related terminology in anesthesia.
5 May, 2022 | 09:51h | UTC
WHO calls for shorter drug course for resistant TB.
4 May, 2022 | 11:08h | UTCWHO calls for shorter drug course for resistant TB – CIDRAP
Rapid communication: Key changes to the treatment of drug-resistant tuberculosis – World Health Organization
Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection.
4 May, 2022 | 10:36h | UTC
Commentary on Twitter (thread – click for more)
https://twitter.com/JessicaLittleMD/status/1521513877242101762
Review: Opioids and falls risk in older adults.
4 May, 2022 | 10:27h | UTCOpioids and Falls Risk in Older Adults: A Narrative Review – Drugs & Aging
Cohort Study: Characterizing older adults’ risk of harm from blood-pressure lowering medications.
4 May, 2022 | 10:26h | UTC
Cohort study: frailty is significantly associated with medication-related harm.
4 May, 2022 | 08:17h | UTC
Remdesivir and three other drugs for hospitalized patients with COVID-19: final results of the WHO Solidarity randomized trial and updated meta-analyses.
3 May, 2022 | 11:18h | UTCInvited Commentary: When and which patients should receive remdesivir? – The Lancet
M-A of randomized trials: association of influenza vaccination with cardiovascular risk.
3 May, 2022 | 10:58h | UTCAssociation of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis – JAMA Network Open
Commentary on Twitter
In this meta-analysis, seasonal flu vaccine was associated with a 34% reduced risk of major adverse cardiovascular events in 1 year, with the biggest difference in patients with recent acute coronary syndrome. @WCHResearch @PMunkCardiacCtr https://t.co/SPrXNfMQJS
— JAMA Network Open (@JAMANetworkOpen) April 29, 2022
Review: Equianalgesia, opioid switch and opioid association in different clinical settings.
3 May, 2022 | 10:42h | UTC
Pfizer says COVID treatment Paxlovid fails to prevent infection of household members.
2 May, 2022 | 00:43h | UTCPfizer says COVID treatment Paxlovid fails to prevent infection of household members – Reuters
Commentary on Twitter
Pfizer Inc on Friday said a large trial found that its COVID-19 oral antiviral treatment Paxlovid was not effective at preventing coronavirus infection in people living with someone who had been exposed to the virus. https://t.co/95zphEYaxc
— Reuters Health (@Reuters_Health) April 29, 2022
RCT: Phentermine/Topiramate for the treatment of adolescent obesity.
2 May, 2022 | 00:41h | UTCPhentermine/Topiramate for the Treatment of Adolescent Obesity – NEJM Evidence
Commentary on Twitter
This RCT evaluated phentermine/topiramate in adolescents ages 12 to <17 yrs with high BMIs over a 56 week period. At both mid- and top-doses, treatment significantly reduced BMI and waist circumference compared to placebo. https://t.co/HbCZOAlZPf@PedsEndoSociety #PedsEndo2022 pic.twitter.com/nB5juqxyA0
— NEJM Evidence (@NEJMEvidence) April 30, 2022
RCT: Extended vs. standard antibiotic course duration in children below 5 years of age hospitalized with community-acquired pneumonia in high-risk settings.
29 Apr, 2022 | 11:16h | UTCRelated:
Treatment of UTIs in Infants <2 Months: A Living Systematic Review – Hospital Pediatrics
Commentary on Twitter
15th RCT of short course therapy for CAP just published, this one another peds study (3 mo to <5 yr). 5-6 d vs. 14 days. Guess what the outcome was??? Updated tables will be tweeted out soon!@ABsteward @DoctorRachael @medrants https://t.co/br4WAEXAzJ
— Brad Spellberg (@BradSpellberg) April 28, 2022
WHO reveals shocking extent of exploitative formula milk marketing.
29 Apr, 2022 | 10:58h | UTCNews Release: WHO reveals shocking extent of exploitative formula milk marketing – World Health Organization
Commentary on Twitter (thread – click for more)
🆕 WHO report reveals shocking extent of exploitative formula milk marketing
The formula milk industry, valued at US$55 billion, is paying social media platforms & influencers to gain direct access to pregnant women & mothers.#EndExploitativeMarketing
👉https://t.co/0dciNxB0fQ pic.twitter.com/hhAnyp0ueH— World Health Organization (WHO) (@WHO) April 29, 2022
Review: Understanding vaccine safety and the roles of the FDA and the CDC.
29 Apr, 2022 | 11:13h | UTCUnderstanding Vaccine Safety and the Roles of the FDA and the CDC – New England Journal of Medicine
Commentary on Twitter
Development and public acceptance of vaccines are crucial for disease control. Cody Meissner, M.D., reviews the process of evaluating vaccine safety and efficacy and factors that advisory bodies consider in making recommendations. https://t.co/ITqpGthoac pic.twitter.com/HTkyAaWvDO
— NEJM (@NEJM) April 28, 2022
Covid-19: What is the evidence for the antiviral Paxlovid?
28 Apr, 2022 | 10:58h | UTCCovid-19: What is the evidence for the antiviral Paxlovid? – The BMJ
Related:
Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations
A living WHO guideline on drugs for covid-19 – The BMJ
Experts fear U.S. may default to annual Covid boosters without sufficient data.
28 Apr, 2022 | 10:51h | UTCExperts fear U.S. may default to annual Covid boosters without sufficient data – STAT
Commentary on Twitter
Vaccine experts are concerned the U.S. may be sleepwalking into a policy of recommending annual Covid-19 vaccine boosters — without having generated the evidence to show they are actually needed. https://t.co/3TiNZvP0HY
— STAT (@statnews) April 26, 2022
Sodium-glucose Co-transporter 2 Inhibitors in acute heart failure: A review of the available evidence and practical guidance on clinical use.
28 Apr, 2022 | 08:15h | UTC
Commentary on Twitter
#RCM – Vol. 23 No. 4
📑Review
Sodium-glucose Co-transporter 2 Inhibitors in Acute Heart Failure: A Review of the Available Evidence and Practical Guidance on Clinical Use#SGLT2Inhibitor #HeartFailureFulltext:https://t.co/Y997Js75GG pic.twitter.com/61gieE7Mcv
— Reviews in Cardiovascular Medicine (@RCMjournal) April 27, 2022
Phase 2b trial: Prefusion F protein–based respiratory syncytial virus immunization in pregnancy.
28 Apr, 2022 | 08:09h | UTCPrefusion F Protein–Based Respiratory Syncytial Virus Immunization in Pregnancy – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: RSV Prefusion F Protein-Based Immunization Studied in Pregnancy – HealthDay
Commentary on Twitter
In pregnant women, RSVpreF vaccine elicited neutralizing antibody responses with efficient transplacental transfer and without evident safety concerns. https://t.co/r8oktZmBZQ pic.twitter.com/UE7ffxYJW6
— NEJM (@NEJM) April 27, 2022
Checkpoint inhibitor–associated arthritis: a systematic review of case reports and case series.
28 Apr, 2022 | 07:58h | UTC
Observational study suggests calcium supplementation may increase adverse outcomes in patients with aortic stenosis.
27 Apr, 2022 | 08:12h | UTCSupplemental calcium and vitamin D and long-term mortality in aortic stenosis – Heart
News Release: Calcium supps linked to earlier death in older people with heart valve disease – BMJ
Cohort Study: Incidence of Guillain-Barré syndrome after Covid-19 vaccination in the vaccine safety datalink.
27 Apr, 2022 | 08:03h | UTC
Commentary on Twitter
This cohort study of #COVID19 vaccine safety surveillance in the US Vaccine Safety Datalink found a small elevated risk of Guillain-Barré syndrome after Janssen/J&J vaccine but not after mRNA COVID-19 vaccines. @KPDOR https://t.co/TTya5BDqeV
— JAMA Network Open (@JAMANetworkOpen) April 26, 2022
Review: Use of antimicrobials for bloodstream infections in the intensive care unit.
27 Apr, 2022 | 01:34h | UTC
Yes, relapses after Paxlovid happen — now what?
26 Apr, 2022 | 08:18h | UTCYes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations
Commentary on Twitter
Some additional thoughts about relapsing Covid19 after treatment with Paxlovid.
Bottom line — *lots* of unknowns, starting w/ how often it happens.
Looking forward to @pfizer sharing further data on the relapsing cases from their EPIC-HR study. https://t.co/1MMhqn4elw
— Paul Sax (@PaulSaxMD) April 25, 2022